Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus
Open Access
- 1 April 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4), 1603-1612
- https://doi.org/10.1128/aac.01625-09
Abstract
Staphylococcus aureus is the causative agent of several serious infectious diseases. The emergence of antibiotic-resistant S. aureus strains has resulted in significant treatment difficulties, intensifying the need for new antimicrobial agents. Toward this end, we have developed a novel chimeric bacteriophage (phage) lysin that is active against staphylococci, including methicillin-resistant S. aureus (MRSA). The chimeric lysin (called ClyS) was obtained by fusing the N-terminal catalytic domain of the S. aureus Twort phage lysin with the C-terminal cell wall-targeting domain from another S. aureus phage lysin (phiNM3), which displayed Staphylococcus -specific binding. ClyS was expressed in Escherichia coli , and the purified protein lysed MRSA, vancomycin-intermediate strains of S. aureus (VISA), and methicillin-sensitive (MSSA) strains of S. aureus in vitro . In a mouse nasal decolonization model, a 2-log reduction in the viability of MRSA cells was seen 1 h following a single treatment with ClyS. One intraperitoneal dose of ClyS also protected against death by MRSA in a mouse septicemia model. ClyS showed a typical pattern of synergistic interactions with both vancomycin and oxacillin in vitro . More importantly, ClyS and oxacillin at doses that were not protective individually protected synergistically against MRSA septic death in a mouse model. These results strongly support the development of ClyS as an attractive addition to the current treatment options of multidrug-resistant S. aureus infections and would allow for the reinstatement of antibiotics shelved because of mounting resistance.This publication has 47 references indexed in Scilit:
- Genetic analysis of high-level mupirocin resistance in the ST80 clone of community-associated meticillin-resistant Staphylococcus aureusJournal of Medical Microbiology, 2010
- The Persistent Legacy of the 1918 Influenza VirusThe New England Journal of Medicine, 2009
- Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospectsJournal of Antimicrobial Chemotherapy, 2009
- Phage Lysin LysK Can Be Truncated to Its CHAP Domain and Retain Lytic Activity against Live Antibiotic-Resistant StaphylococciApplied and Environmental Microbiology, 2009
- Role ofmgrAandsarAin Methicillin‐ResistantStaphylococcus aureusAutolysis and Resistance to Cell Wall–Active AntibioticsThe Journal of Infectious Diseases, 2009
- Are Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Replacing Traditional Nosocomial MRSA Strains?Clinical Infectious Diseases, 2008
- Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in TaiwanJournal of Clinical Microbiology, 2008
- Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community-Acquired Methicillin-Resistant Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Staphylococcus aureus Mutants with Increased Lysostaphin ResistanceJournal of Bacteriology, 2006
- Peptidoglycan Hydrolase Fusions Maintain Their Parental SpecificitiesApplied and Environmental Microbiology, 2006